Article
On the final day of ACR25, late-breaking abstract #24 drew particular attention, presenting results from the first positive Phase 3 trials of a potential systemic treatment for a disease that has long lacked one.
All News
Article
In the phase 2 PAISLEY trial, deucravacitinib met its primary and secondary endpoints, demonstrating efficacy across multiple clinical and patient-reported outcomes. However, the impact on renal function has remained unclear. An abstract presented at ACR provides new insights.
Article
Giant cell arteritis (GCA) is the most common form of adult vasculitis in the United States and can be subdivided into those with cranial only symptoms, those with large vessel vasculiti/PMR, and those with mixed features.
Dr. John Cush
Tweet
IgG4: Rare, but new treatments on the horizon
IgG4 is a rare autoimmune disease with excessive IgG4 immunoglobulins that can affect multiple organs yielding plasma cell deposition (inflammation) and fibrosis.
https://t.co/v07Kp5tQXg https://t.co/rIvOF0mrM1
Dr. John Cush
Tweet
Do Patients with Rheumatic Diseases 'Weather' the Storm?
Dr. Janet Pope reports on abstract 0164 (Online Patient Survey on the Impact of Extreme Weather Events on Autoimmune and Rheumatic Diseases) presented at #acr25.
https://t.co/rY3T6tWsgu https://t.co/vdgT2DB5lH
Dr. John Cush
Tweet
Upadacitinib: revisiting safety data in RA and GCA
For the last several years, conversations about JAK inhibitors have often started and ended with safety. The shadow cast by ORAL Surveillance has made clinicians more cautious and regulators more restrictive. Yet in practice, https://t.co/6Wes2npkFd
Dr. John Cush
Tweet
#ACR25 Best Abstracts - Day 3
Tweeting about an ACR presentation or poster is a skill and sometimes art -- one that is mastered by the RheumNow faculty roving the halls and floors for the best new insights at #ACR25, Here are several of the best abstracts from Day 3, as chosen https://t.co/fOgXSiIWzC
Dr. John Cush
Tweet
Replay of RheumNow Live 2025 - Rheumatoid Arthritis https://t.co/TMC0A11Eil
Dr. John Cush
Tweet
Accelerated Aging in Rheumatic Disease: From Biology to Lifestyle Intervention
At #ACR25, the session “27M02: Nutrition for Rheumatic Disease: Where Aging Biology, Sarcopenia, and Diet Intersect” invited the audience to view rheumatic disease through the lens of biological https://t.co/OIgh8JQsFa
Dr. John Cush
Tweet
A Halloween ACR Guidance (10.31.25)
Dr. Jack Cush recaps #ACR25 with suggestions on how to best learn ACR25 content from RheumNow and our Videos and podcasts.
https://t.co/ik5n4jA3LK https://t.co/lr65m8kRxx
Dr. John Cush
Tweet
The Great Debate – Who Really Won? #ACR25
https://t.co/bh0wxXpVXa https://t.co/Wr8eeW1KsQ
Dr. John Cush
Tweet
The Decade Ahead: Predicting Long-Term Proteinuria Risk in SLE
Lupus nephritis affects almost half of patients with SLE and conveys a mortality rate of up to 30% at 10 years, with at least 10-22% of patients developing end-stage kidney disease. Early detection and diagnosis are https://t.co/ggoA2KsqXg
Dr. John Cush
Tweet
Belimumab Before or After Immunosuppressant
Dr. Yuz Yusof reports on abstract 0803 presented at #ACR25
https://t.co/BVFhDDfTvW https://t.co/F9ZvGXIqVn
Dr. John Cush
Tweet
Using AI and LLMs in Qualitative Data
Dr. Bella Mehta discusses abstract 0794 (Using AI to Analyze Multilingual Qualitative Data in Lupus Pregnancy Research: A Proof of Concept with Large Language Models) presented at #ACR25
https://t.co/HFBuNxdZOF https://t.co/gKAXURq8xR
Dr. John Cush
Tweet
If We Can’t Prevent RA, Can We at Least Prevent Difficult-to-Treat RA?
Despite major advances in RA management, some patients develop difficult-to-treat RA (D2TRA), characterized by ongoing inflammation and impairment despite multiple therapies. While understanding of the https://t.co/FcF0V82KdT
Dr. John Cush
Tweet
The Long View of Diagnostic Delay in Axial Spondyloarthritis
At #ACR25, Abstract #1407 presented a cross-sectional analysis from the Brazilian Spondyloarthritis Registry (RBE), offering a unique perspective on how diagnostic patterns have evolved over six decades. https://t.co/7ttYXJtfpc
Dr. John Cush
Tweet
#ACR25 – Day 2 Report
Here are 3 abstracts that caught my eye on Day 2 at #ACR25. Notably these have takeaway messages that should support your current practices.
https://t.co/xKPAgeWudD https://t.co/Fb16l6A252
Dr. John Cush
Tweet
Cellular Biomarkers of Rheumatoid Arthritis
Dr. Jeffrey Sparks reports on four abstracts at #ACR25.
https://t.co/ZO259DXIcW https://t.co/HOpgiXfYvM
Dr. John Cush
Tweet
PsA: Impact of Sex
Dr. Arthur Kavanaugh highlights the importance of sex on disease characteristics and response to therapy in psoriatic arthritis, reporting from #ACR25.
https://t.co/QtU4iATexR https://t.co/uCJsxYpFTc
Dr. John Cush
Tweet
Nerandomilast for ILD
Dr. Mike Putman reports on abstract 1662 (Efficacy and Safety of Nerandomilast in Patients with Autoimmune Disease-Related Progressive Pulmonary Fibrosis: Subgroup Analysis of the FIBRONEER-ILD trial). #ACR25
https://t.co/J0e4SbVgFE https://t.co/dlOM700yVQ
